The engineered single guide RNA structure as a biomarker for gene-editing reagent exposure.

Sci Rep

Molecular and Microbiology, Sandia National Laboratories, Albuquerque, NM, 87185, USA.

Published: July 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

CRISPR arrays and CRISPR-associated (Cas) proteins comprise a prevalent adaptive immune system in bacteria and archaea. These systems defend against exogenous parasitic mobile genetic elements. The adaption of single effector CRISPR-Cas systems has massively facilitated gene-editing due to the reprogrammable guide RNA. The guide RNA affords little priming space for conventional PCR-based nucleic acid tests without foreknowledge of the spacer sequence. Further impeding detection of gene-editor exposure, these systems are derived from human microflora and pathogens (Staphylococcus pyogenes, Streptococcus aureus, etc.) that contaminate human patient samples. The single guide RNA-formed from the CRISPR RNA (crRNA) and transactivating RNA (tracrRNA)-harbors a variable tetraloop sequence between the two RNA segments, complicating PCR assays. Identical single effector Cas proteins are used for gene-editing and naturally by bacteria. Antibodies raised against these Cas proteins are unable to distinguish CRISPR-Cas gene-editors from bacterial contaminant. To overcome the high potential for false positives, we have developed a DNA displacement assay to specifically detect gene-editors. We leveraged the single guide RNA structure as an engineered moiety for gene-editor exposure that does not cross-react with bacterial CRISPRs. Our assay has been validated for five common CRISPR systems and functions in complex sample matrices.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319717PMC
http://dx.doi.org/10.1038/s41598-023-37525-yDOI Listing

Publication Analysis

Top Keywords

guide rna
16
single guide
12
cas proteins
12
rna structure
8
single effector
8
gene-editor exposure
8
rna
7
guide
5
engineered single
4
structure biomarker
4

Similar Publications

Atherosclerosis, a major cause of cardiovascular diseases, is characterized by the buildup of lipids and chronic inflammation in the arteries, leading to plaque formation and potential rupture. Despite recent advances in single-cell transcriptomics (scRNA-seq), the underlying immune mechanisms and transformations in structural cells driving plaque progression remain incompletely defined. Existing datasets often lack comprehensive coverage and consistent annotations, limiting the utility of downstream analyses.

View Article and Find Full Text PDF

EASY-edit: a toolbox for high-throughput single-step custom genetic editing in bacteria.

Nucleic Acids Res

September 2025

Expression génétique microbienne, UMR8261 CNRS, Université Paris Cité, Institut de Biologie Physico-Chimique, Paris 75005, France.

Targeted gene editing can be achieved using CRISPR-Cas9-assisted recombineering. However, high-efficiency editing requires careful optimization for each locus to be modified, which can be tedious and time-consuming. In this work, we developed a simple, fast and cheap method: Engineered Assembly of SYnthetic operons for targeted editing (EASY-edit) in Escherichia coli.

View Article and Find Full Text PDF

CRISPR/Cas12a DTR system: a topology-guided Cas12a assay for specific dual detection of RNA and DNA targets.

Nucleic Acids Res

September 2025

State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Hubei 430042, China.

The CRISPR/Cas12a technology has revolutionized molecular diagnostics. However, existing Cas12a systems depend on continuous target DNA activation, which limits them to single-target detection. In this study, we developed a novel topology-guided Cas12a system, the double-target responsive (DTR) system, capable of being activated by noncontiguous dual RNA/DNA targets.

View Article and Find Full Text PDF

Bladder cancer (BC) remains a common malignancy, with muscle-invasive bladder cancer (MIBC) comprising 20 % of cases and a poor 5-year survival rate of ∼50 %. While neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard treatment for locally advanced disease, NAC is limited by toxicity and non-response in many patients. Predictive biomarkers are urgently needed to guide treatment decisions.

View Article and Find Full Text PDF